Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1 , 2 , 3 , 4 …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…

Durability of Response after Ad26.COV2.S Vaccination In this study, investigators measured
immune responses in 20 participants who had received either one or two doses of the Ad26.…

Importance Developing effective vaccines against Ebola virus is a global priority. Objective
To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV…

The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases
(EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, …

Background Despite the availability of effective vaccines against COVID-19, booster
vaccinations are needed to maintain vaccine-induced protection against variant strains and …